Management of Pulmonary Nodules by Community Pulmonologists A Multicenter Observational Study by Tanner, Nichole T. et al.
 journal.publications.chestnet.org  1405 
 Management of Pulmonary Nodules by Community 
Pulmonologists 
 A Multicenter Observational Study 
 Nichole T.  Tanner ,  MD ,  MSCR ;  Jyoti  Aggarwal ,  MHS ;  Michael K.  Gould ,  MD ;  Paul  Kearney ,  PhD ; 
 Gregory  Diette ,  MD ,  MHS ;  Anil  Vachani ,  MD ;  Kenneth C.  Fang ,  MD ; and  Gerard A.  Silvestri ,  MD 
 BACKGROUND:  Pulmonary nodules (PNs) are a common reason for referral to pulmonologists. 
Th e majority of data for the evaluation and management of PNs is derived from studies per-
formed in academic medical centers. Little is known about the prevalence and diagnosis of 
PNs, the use of diagnostic testing, or the management of PNs by community pulmonologists. 
 METHODS:  Th is multicenter observational record review evaluated 377 patients aged 40 to 
89 years referred to 18 geographically diverse community pulmonary practices for interme-
diate PNs (8-20 mm). Study measures included the prevalence of malignancy, procedure/test 
use, and nodule pretest probability of malignancy as calculated by two previously validated 
models. Th e relationship between calculated pretest probability and management decisions 
was evaluated. 
 RESULTS:  Th e prevalence of malignancy was 25% (n  5 94). Nearly one-half of the patients 
(46%, n  5 175) had surveillance alone. Biopsy was performed on 125 patients (33.2%). A total 
of 77 patients (20.4%) underwent surgery, of whom 35% (n  5 27) had benign disease. PET 
scan was used in 141 patients (37%). Th e false-positive rate for PET scan was 39% (95% CI, 
27.1%-52.1%). Pretest probability of malignancy calculations showed that 9.5% (n  5 36) were 
at a low risk, 79.6% (n  5 300) were at a moderate risk, and 10.8% (n  5 41) were at a high risk 
of malignancy. Th e rate of surgical resection was similar among the three groups (17%, 21%, 
17%, respectively;  P  5 .69). 
 CONCLUSIONS:  A substantial fraction of intermediate-sized nodules referred to pulmonolo-
gists ultimately prove to be lung cancer. Despite advances in imaging and nonsurgical biopsy 
techniques, invasive sampling of low-risk nodules and surgical resection of benign nodules 
remain common, suggesting a lack of adherence to guidelines for the management of PNs. 
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 A pulmonary nodule (PN) is defi ned as a radiographic 
opacity   3 cm in diameter surrounded by lung paren-
chyma. 1 Th e prevalence of PNs is unknown, with estimates 
ranging from 150,000 to 1 million per year in the United 
States. 2 Th e identifi cation of PNs may increase over the 
next decade for several reasons. First, chest CT scans are 
ordered frequently for a myriad of clinical indications, 
including dyspnea or chest pain. Smith-Bindman et al 3 
estimate the rate of chest CT scanning as 23 per 1,000, 
which, extrapolated to the US population, equates to 
approximately 7 million chest CT scans performed 
annually. Second, the National Lung Screening Trial 
found three fewer deaths from lung cancer per 1,000 in 
those screened annually for 3 years with low-dose chest 
CT scans, leading to the B recommendation by the 
US Preventive Services Task Force 4 to screen high-risk 
individuals with yearly low-dose CT scans. However, 
the National Lung Screening Trial also found a 25% rate 
of screen-detected nodules, 96% of which were benign. 
Currently, 8.6 million Americans meet the criteria for 
screening. 5 Depending on the penetration of screening, 
the incidence of detected PNs could increase dramatically. 6 
 Th e American College of Chest Physicians (CHEST) and 
the Fleischner Society have published guidelines for 
management based on pretest probability of malignancy 
(pCA). 7,8 Management decisions fall into three general cate-
gories based on the physician’s pCA. For those in whom 
the pCA is low, serial imaging is recommended. When 
 Materials and Methods 
 Th is was a multicenter, community-based, retrospective observational 
study of patients with PNs, ranging from 8 to 20 mm in diameter, present-
ing to 18 geographically representative outpatient pulmonary clinics 
across the United States. Th e study was approved at 15 sites by a central 
institutional review board and at three sites by local institutional review 
board approval. 
 Site Selection 
 Four hundred forty sites were identifi ed based on investigator data-
bases and claims data from a large insurance carrier whose coverage 
population was representative of the overall US population. Of these, 
77 sites expressed interest in participating, and 48 sites went on to sign 
confidentiality agreements. Of these, 17 did not request additional 
information, leaving 31 sites undergoing qualifi cation review. Eighteen 
outpatient pulmonary clinics were chosen to participate based on the 
following criteria: (1) management of patients with PNs, (2) availability 
of medical records, and (3) ability to perform data abstraction. In 
addition, investigators targeted enrollment of geographically diverse 
patients to limit the potential bias associated with diff erences in practice 
patterns and to account for variation in disease prevalence (eg, endemic 
mycoses) that could alter management decisions. 
 Patient Selection 
 Patients were identifi ed by querying databases (eg, billing and schedul-
ing systems) using fi ve  International Classifi cation of Diseases , Ninth 
Revision , Clinical Modifi cation codes for PN (793.1, 786.6, 518.89, 519.8, 
519.9) to ensure homogeneity in patient identifi cation and inclusion. 17 
Manual chart abstraction was then used to identify those who met the 
criteria. To minimize selection bias, the sites were not permitted to use 
additional codes during database query to identify patients. To ensure 
a systematic sample, patient eligibility was determined by examining 
consecutively referred patients to the site. 
 Inclusion criteria included age   40 years and   89 years at the time 
of nodule fi nding, presentation to a pulmonologist, nodule size 8 to 
20 mm, and definitive diagnosis ascertained by tissue diagnosis or 
radiographic follow-up for 2 years. Exclusion criteria included chest 
CT scan performed  . 60 days prior to the initial visit, prior diagnosis 
of any cancer within 2 years of nodule detection, or incomplete chart data. 
 Patients were categorized into three groups by the most invasive pro-
cedure performed during management, as follows: surveillance (serial 
imaging), biopsy (CT scan-guided transthoracic needle aspiration 
[TTNA] or bronchoscopy), or surgery (including mediastinoscopy, 
video-assisted thorascopic surgery, and/or thoracotomy). 
 Data Collection 
 Clinical data were abstracted retrospectively by designated study 
staff  into an electronic data capture system from initial consultation 
through establishment of a defi nitive diagnosis (ie, pathology results) 
or a minimum 2-year follow-up. Data included patient demographic 
and clinical characteristics, PN characteristics, imaging tests, invasive 
testing, and surgery. PET scan reports were reviewed and abstracted 
where available for a subset of patients. To adjudicate a PET scan 
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the pCA is intermediate, functional imaging (PET scan), 
biopsy, or both is warranted. When the pCA is high, sur-
gery is recommended. 8 Although these recommendations 
appear straightforward, other factors such as patient 
comorbidities and preferences oft en infl uence the choice 
of management strategy. 8 Clinical prediction models have 
been developed and validated to assess the pCA in PNs, 
which can be used to help guide decisions about selection 
and interpretation of additional diagnostic testing. 9-12 
 Outside clinical practice guidelines, there remain signifi -
cant challenges in interpretation of the literature. First, 
the prevalence of malignancy in a PN varies by the 
context within which it is studied, from a low of 2% in 
lung cancer screening trials to a high of 83% in surgical 
series. 13-15 Unfortunately, most of these studies are from 
single-center academic institutions focused on a single 
aspect of nodule management (eg, PET scan use) and 
do not always combine modalities to give a cohesive 
picture of how nodules are managed from presentation 
to fi nal outcome. We undertook this study to better 
understand the management patterns of physicians 
faced with the evaluation of intermediate-sized nodules, 
which most oft en present a diagnostic dilemma, 16 in 
community settings across the United States. 
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report as positive or negative, an algorithm was developed that prior-
itized the following components of the report from highest to lowest: 
fi nal radiology impression, description of fi ndings, and standard uptake 
values (SUVs) ( e-Fig 1 ). PET scanning was defi ned as negative if the 
report included any of the following statements: no evidence of malig-
nancy, no 18F-fl uorodeoxyglucose uptake or hypermetabolic activity, 
or an SUV of  , 2.5. A positive PET scan was defi ned as a report that 
included any of the following statements: concern or suggestion of 
malignancy, fi ndings that described increased 18F-fl uorodeoxyglucose 
uptake or hypermetabolic activity, or an SUV   2.5. In the 27 cases 
in which the fi ndings were discordant with the fi nal impression, adju-
dication was performed by two independent pulmonologists and 
agreement was reached in all cases. Data quality was ensured through 
ongoing site monitoring. Programmed edit checks were built into the 
electronic data capture system and at the conclusion of chart abstrac-
tion, each site provided access to a random 10% sample of deidentifi ed 
patient records for review. 
 Pretest Probability of Malignancy 
 Two previously developed and validated models 9,10 were used to esti-
mate the pCA in each patient. Model accuracy was determined by compar-
ing the pCA with the fi nal diagnosis. Receiver operating characteristic 
curves and the area under the curve were generated with 95% CIs. Th e 
pCA was calculated for each patient and categorized into three groups 
( , 5%, 5% to  , 65%, and   65%). Procedure use by group was examined. 
 Data Analysis 
 x 2 or analysis of variance tests were used to compare subgroups, and 
 P values  , .05 were considered signifi cant. A nodule was classifi ed as 
benign based on confi rmed benign pathology or the absence of radio-
graphic change as determined by the managing physician during surveil-
lance for at least 2 years. Multivariate logistic regression was performed 
to identify factors associated with the use of an invasive diagnostic pro-
cedure. All statistical analyses were performed using SAS/STAT, version 
9.3 (SAS Institute inc).  
 Results 
 Eighteen sites were chosen based on geographic loca-
tion and ability to meet the inclusion criteria ( e-Fig 2 ). 
A total of 2,579 patients were screened for eligibility. 
Following review, 377 patients were included in the fi nal 
analysis ( Fig 1 ). Most of the exclusions were based on 
nodule size ( , 8 mm or  . 20 mm) (n  5 1,314), missing 
clinical information (n  5 424), or insuffi  cient follow-up 
time (n  5 303). Th ere was some variation at both the site 
level and regionally in the numbers of patients excluded 
because of missing data ( e-Tables 1, 2 ). 
 Of the 377 patients included, 283 (75%) had a nodule 
that was benign, and 94 (25%) had a malignant nodule 
( Table 1 ). Th e average age was 64.5 years, although 
patients with malignancy were slightly older ( P  , .02). 
Th ere was an equal sex distribution. Th ose with 
cancer were more likely to be current or former smokers 
( P  , .0001). Although the number of pack-years 
smoked was signifi cantly higher in those with malig-
nancy (45 vs 27,  P  , .0001), a substantial proportion of 
those with benign nodules smoked (67%). Malignant 
 Figure 1 – Inclusion and exclusion. Eval  5 evaluation. 
nodules were larger than benign nodules ( P  , .0001), 
although there did not appear to be a reliable cutoff  
above which malignancy could be predicted.  Figure 2 
demonstrates the diagnostic outcome by nodule size. 
Twelve percent of nodules   11 mm in size were malig-
nant, whereas 40% of nodules between 16 and 20 mm 
were malignant. 
 Current smokers (OR  5 3.29; 95% CI, 1.36-7.98) and 
patients with larger nodules (16-20 mm) were more 
likely (OR  5 4.77; 95% CI, 2.95-7.72) to have a proce-
dure (biopsy or surgery) performed. Th ere was no dif-
ference in receipt of procedure based on age, family 
history of cancer, or geographic location ( Table 2 ). 
 To further understand nodule management decisions, 
we used two prediction models to determine the pCA 
for each individual in the study. 9,10 Th ese models had 
very good accuracy in this cohort of patients, with an 
area under the curve of 0.77 (95% CI, 0.72-0.81) and 
0.74 (95% CI, 0.69-0.80), respectively ( e-Fig 3 ). Because 
the results did not vary signifi cantly between models, we 
report the results from the Veteran Aff airs model here 
and results from the Mayo model in  e-Table 3 .  Table 3 
 lists the pretest probability for cancer by three ranges as 
defi ned by the CHEST guidelines for PN management: 
low risk (pCA  , 0.05), intermediate risk (pCA 0.05 
to  , 0.65), and high risk ( . 0.65). 8 Th e average pCA for 
all patients as calculated by the model was 0.33, which 
is only slightly higher than the cancer prevalence of 25% 
in this population. Th irty-six patients had nodules that 
had a low risk of malignancy, and all were benign. Slightly 
more than one-half were followed by serial imaging 
alone (n  5 20, 56%). However, despite a pCA of  , 0.05, 
10 (28%) underwent biopsy, and six (17%) had surgical 
resection. Th e majority of nodules (n  5 300) fell into 
the intermediate-risk category, and 75% of these were 
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 TABLE 1  ]  Characteristics of Patients and Lung Nodules 
Characteristics All Patients Cancer Benign  P  Value
Patients , No. 377 94 283 …
 Age, y 65 (40-88) 67 (42-83) 64 (40-88) .0186
 Sex .9308
  Male 171 (45) 43 (46) 128 (45)
  Female 206 (55) 51 (54) 155 (55)
 Smoking history
  Status  , .0001
   Never 102 (27) 8 (9) 94 (33)
   Former 169 (45) 50 (53) 119 (42)
   Current 106 (28) 36 (38) 70 (25)
  Pack-y, mean (range) 32 (0-165) 45 (0-125) 27 (0-165)  , .0001
 Known family history of lung cancer 46 (12) 19 (20) 27 (10) .0062
 Geographic region .1087
  Midwest 118 (31) 25 (27) 93 (33)
  Northeast 88 (23) 17 (18) 71 (25)
  South 88 (23) 24 (26) 64 (23)
  West 83 (22) 28 (30) 55 (19)
Lung nodules
 Size, mm 13 (8-20) 15 (8-20) 12 (8-20)  , .0001
 Location .0262
  Left lower lobe 76 (20) 14 (15) 62 (22)
  Left upper lobe 91 (24) 29 (31) 62 (22)
  Right lower lobe 77 (20) 16 (17) 61 (22)
  Right middle lobe 45 (12) 6 (6) 39 (14)
  Right upper lobe 88 (23) 29 (31) 59 (21)
 Spiculated 118 (31) 45 (48) 73 (26)  , .0001
Diagnosis
 Clinical benign 175 (46) … 175 (62) …
 Histopathology
  Benign diagnosis …
   No malignancy 21 (6) … 21 (7)
   Infection/inﬂ ammation 22 (6) … 22 (8)
   Granuloma 7 (2) … 7 (2)
   Scar 1 (0) … 1 (0)
   Nondiagnostic biopsy/radiographically 
   stable or resolved at 2 y
57 (15) … 57 (20)
  Cancer diagnosis …
   NSCLC (type not speciﬁ ed) 57 (15) 57 (61) …
   NSCLC (bronchial alveolar carcinoma) 2 (1) 2 (2) …
   Adenocarcinoma 14 (4) 14 (15) …
   Squamous cell 10 (3) 10 (11) …
   Small cell 4 (1) 4 (4) …
   Other a 7 (2) 7 (7) …
(Continued)
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Characteristics All Patients Cancer Benign  P  Value
Procedure use
 Surgery 77 (20) 50 (53) 27 (10)  , .0001
 Biopsy 144 (38) 55 (59) 89 (32)  , .0001
 Surgery or biopsy 202 (54) 94 (100) 108 (38)  , .0001
 PET scan 141 (37) 56 (60) 85 (30)  , .0001
 CT scan/radiograph only 133 (35) 0 (0) 133 (47)  , .0001
 Procedure use category
  Most invasive  5 surgery 77 (20) 50 (53) 27 (10)  , .0001
  Most invasive  5 biopsy 125 (33) 44 (47) 81 (29) .0012
  Surveillance 175 (46) 0 (0) 175 (62)  , .0001
 Data are given as No. (%) or mean (range) unless otherwise indicated. NSCLC  5 non-small cell lung cancer. 
  a Other cancer diagnoses include spindle cell, mesothelioma, and metastatic cancer. 
TABLE 1 ] (continued)
 Figure 2 – Diagnostic outcome by 
nodule size (N  5 377). 
benign. Forty-one patients (11%) had high-risk nodules, 
and 23 (58%) were benign. Th e rate of surgical resection 
was similar among the three groups (17%, 21%, 17%, 
respectively;  P  5 .69). Alternative cut points for the 
low-risk category were investigated. All nodules with a 
pCA of  , 0.10 were found to be benign, whereas 98% of 
those with a pCA of  , 0.15 were benign ( Table 4 ). 
 Nearly one-half of all patients (46%, n  5 175) were 
followed with serial imaging only. Th e median number 
of scans performed was three (range, one to seven). 
Although the majority (62%) had three to fi ve follow-up 
imaging studies, 4% underwent seven repeat scans. 
All nodules in this group were benign by resolution or 
2 years of radiographic stability. Biopsy (TTNA or bron-
choscopy) was performed as the most invasive procedure 
in 125 patients (33%) and was positive for malignancy 
in 44 (35%). In more than one-half (n  5 71, 57%), a 
specifi c benign diagnosis was obtained, whereas 10 (8%) 
were nondiagnostic and subsequently followed for 
2 years. 
 A total of 77 patients (20%) had surgery as their 
most invasive test. Prior to surgery, 19 patients (25%) 
underwent a TTNA or bronchoscopy; 11 had a nondi-
agnostic biopsy (seven malignant, four benign at 
surgery), and eight had a benign biopsy result (three 
malignant, fi ve benign at surgery). Overall, malignancy 
was diagnosed in 65% (n  5 50; 95% CI, 53.2%-75.5%) 
of those who received surgery, whereas 35% (n  5 27; 
95% CI, 24.5%-46.8%) underwent surgery for benign 
disease. 
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 A PET scan was performed in 141 patients (37%). Over-
all, PET scan use increased with the intensity of testing 
(surveillance 24%, biopsy 42%, surgery 60%,  P  , .0001). 
Results were available for 78% (n  5 110) of those who 
underwent PET scanning ( Fig 3 ) . Th e overall accuracy 
of PET scanning was 74%, with a false-positive (FP) 
rate of 39% and a false-negative (FN) rate of 9%. In 8- to 
11-mm nodules with PET scan data (n  5 38), the FN 
rate was 10% and the FP rate was 36%. Nodules mea-
suring  . 11 to 15 mm (n  5 48) had FN and FP rates of 
9% and 36%, respectively. The FN rate for PET scans 
in nodules  . 15 mm (n  5 24) was 8%, and the FP rate 
was 55%. 
 In the surveillance group (n  5 175), 42 (24%) under-
went PET scanning, for whom 31 reports were available. 
Seven (23%) had PET scan positive results and were 
followed with serial imaging. Among the 125 patients 
who underwent biopsy as the most invasive procedure, 
53 (42%) underwent PET scan prior to the biopsy. 
Results were available in 42 cases. Twenty-nine (69%) 
 TABLE 2  ]  Factors Associated With the Decision 
to Pursue Invasive Procedures in the 
Management of PNs 
Predictor Variable
Multivariable Model
OR 95% CI 
Age
   50 y Reference …
 50-64 y 0.617 0.196-1.941
 64-79 y 0.623 0.226-1.714
   80 y 0.854 0.244-2.993
Smoking history
 Never Reference …
 Former 1.343 0.627-2.875
 Current 3.290 1.357-7.978
Nodule size
 8-11 mm Reference …
 12-15 mm 3.487 2.338-5.200
 16-20 mm 4.773 2.950-7.722
Family history of 
  lung cancer
 No Reference …
 Yes 2.042 0.668-6.238
Region
 Northeast Reference …
 West 1.222 0.365-4.089
 South 0.620 0.263-1.460
 Midwest 0.714 0.330-1.545
 PN  5 pulmonary nodule. 
were PET scan positive and 13 (31%) were negative, yet 
all went on to biopsy. In the 77 patients who underwent 
surgery, 46 (60%) underwent a preoperative PET scan, 
for which 37 reports were available. Th irty-one (84%) 
had PET scan positive results. Among the 19 patients 
who underwent preoperative biopsy, 16 had a PET scan, 
with results available in 15. Th e majority (n  5 14) were 
positive. 
 Discussion 
 Th is study describing the management of intermediate 
PNs referred to community pulmonologists has several 
important fi ndings. First, a quarter of patients referred 
for intermediate-sized PN evaluation were found to 
have cancer, emphasizing the importance of the diag-
nostic evaluation. Second, 35% of patients who 
underwent surgery had benign nodules. Th ird, despite 
guideline recommendations for surveillance of PNs with 
 , 5% pCA, 44% of low-risk patients underwent one or 
more invasive procedures for a benign nodule. Finally, 
the rate of surgical resection for nodules with various 
pretest probabilities of malignancy was similar. Th is 
suggests that pulmonologists do not routinely consider 
pCA, are unaware that guidelines exist for nodule man-
agement, or do not to follow them. 
 To our knowledge, this is the first study that docu-
ments the prevalence of cancer (25%) in patients 
with intermediate-sized nodules who are referred to 
community-based pulmonologists. Th is fi nding has impli-
cations for managing PNs in the community; because the 
risk of cancer is substantial, patients should be managed 
based on their individualized risk of malignancy. 
 We found that a high proportion of patients who under-
went surgery had benign disease without variation when 
stratifi ed by the pretest probability of cancer in the nod-
ule. Th e rates of resection for benign disease varied from 
9% to 23% in screening trials and surgical series. 14,18 
Guidelines recommend surgery if the pretest probability 
of cancer is high (pCA  . 65%) because a negative biopsy 
result would not dissuade the physician from pursuing a 
defi nitive diagnosis and a positive biopsy result would 
lead to surgery anyway. 
 Th e risk models we evaluated were very good at identi-
fying those patients who did not have cancer (100% 
nodules with  , 5% pCA were benign), yet surgical 
resection was performed at rates similar to those with 
a high probability of cancer. Similarly, there was no 
diff erence in the proportion of patients undergoing 
surveillance when stratifi ed by pCA. Th is suggests that 
pulmonologists did not readily follow the guidelines 
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because they were unaware of them, did not believe 
them useful, or overestimated the pCA. Th is study does 
not allow us to explore the reasons why pulmonologists 
aggressively manage some nodules that turn out to be 
benign. Th ere are several possible explanations as to 
what may have led to biopsy or surgery, and they include 
being misled by PET scan results, patient preferences 
for diagnostic certainty, an overestimation of the pCA, 
or incentives for procedure referral. 19 Further research 
is needed to determine the exact drivers of physician 
decision-making in PN management. 
 Although physicians did not appear to use pCA in 
making decisions about surgery or surveillance, there 
was a trend toward an increasing use of biopsy as the 
pCA increased ( P  5 .07). Th is fi nding suggests that pul-
monologists may use clinical intuition and experience 
to distinguish benign from malignant disease, although, 
admittedly, data on provider years in practice and the 
proportion who were board certifi ed were not available. 
A signifi cant proportion of patients in this study with 
benign nodules were older and had signifi cant smoking 
histories and larger nodules, all which typically suggest 
 TABLE 3  ]  Calculated Pretest Probability and Procedure Use 
Variables
Clinical Probability of Cancer 
 P Value , 0.05 (n  5 36) 0.05 to  , 0.65 (n  5 300)   0.65 (n  5 41)
VA model probability, pCA 0.03   0.013 0.32   0.162 0.74   0.056 …
Outcome
 Benign 36 (100) 224 (75) 23 (58)  , .0001
 Malignant 0 (0) 76 (25) 18 (45)  , .0001
Age 55.1   12.74 64.2   10.10 74.6   6.66  , .0001
Smoking status
 Ever 11 (31) 223 (74) 41 (100)  , .0001
 Never 25 (69) 77 (26) 0 (0)  , .0001
 Years of abstinence a 27.1   42.79 7.8   13.07 3.9   6.60  , .0001
 Pack-y 6.4   13.92 32.6   32.42 46.8   21.44  , .0001
Nodule size 10.6   2.99 12.6   3.63 16.1   3.32  , .0001
Procedure use b 
 Surgery 6 (17) 64 (21) 7 (17) .6878
 Biopsy 11 (31) 112 (37) 21 (51) .1401
 Surgery or biopsy 16 (44) 159 (53) 27 (66) .1548
 PET scan 13 (36) 113 (38) 15 (37) .9771
 CT scan/radiograph only 15 (42) 107 (36) 11 (27) .3781
Procedure use category b 
 Most invasive  5 surgery 6 (17) 64 (21) 7 (17) .6878
 Most invasive  5 biopsy 10 (28) 95 (32) 20 (49) .0711
 Surveillance 20 (56) 141 (47) 14 (34) .1548
 Data are given as No. (%) or mean   SD. pCA  5 pretest probability of malignancy; VA  5 Veterans Aﬀ airs .  
 a Both never smokers and current smokers are included. 
 b Diﬀ erences are not statistically signiﬁ cant,  P  . .05. 
 TABLE 4  ]  Alternative Pretest Probabilities for Low-Risk Category 
Variables 
Clinical Probability for Cancer
 , 0.05 (n  5 36)  , 0.10 (n  5 61)  , 0.15 (n  5 93)  , 0.20 (n  5 127)   , 0.25 (n  5 160)
VA model probability, pCA 0.03   0.013 0.05   0.030 0.07   0.045 0.10   0.059 0.13   0.073
Outcome
 Benign 36 (100) 61 (100) 91 (98) 121 (95) 150 (94)
 Malignant 0 (0) 0 (0) 2 (2) 6 (5) 10 (6)
 Data are given as No. (%) or mean   SD. See  Table 3 for expansion of abbreviations. 
 1412  Original Research  [   1 4 8  #  6   C H E S T   D E C E M B E R   2 0 1 5   ] 
malignancy and may have led physicians to overesti-
mate pCA. 
 In the setting of a positive or ambiguous PET scan 
interpretation, it is possible that the pulmonologists felt 
compelled to confi rm the abnormal fi ndings with a 
defi nitive tissue diagnosis. Th e FP rate for PET scans 
in this study was 39%, as compared with the 5% to 28% 
rate 20-26 reported in the literature. Conversely, in some 
instances, PET scan results did not seem to be taken 
into account when making management decisions. For 
instance, in the surveillance-only group, eight patients 
with positive PET scans did not undergo further diagnos-
tic procedures. Similarly, in the biopsy group, 13 patients 
with negative PET scan results still underwent an inva-
sive procedure. Another consideration is that patient 
preferences infl uenced the decision toward more aggres-
sive care. Th e guidelines advocate a patient-centered 
approach to decision-making aft er patients are informed 
of the pCA. 8 Th us, some patients may request surgery 
despite a low pCA because of anxiety about the unknown 
and an unwillingness to continue with surveillance. 27 
Th e cornerstone of management for PNs has been calcu-
lating pCA and acting on those calculations. 8 Th is study 
provides evidence that physicians may not use pCA to 
guide decision-making and also suggests that an alter-
native low-risk-category pCA higher than the current 
CHEST guidelines would shift  more patients into the 
surveillance management strategy without missing 
malignancy. 
 Although the exact reason for management decisions 
cannot be elicited, it is clear that there is wide variation 
in the management of PNs by pulmonologists. Th e goal 
for nodule management is to effi  ciently detect lung can-
cer while decreasing the number of unnecessary invasive 
procedures. A number of radiographic improvements, 
novel tests, and biomarkers have been developed with 
the potential to help determine the likelihood of malig-
nancy in a nodule. Th e use of semiautomated volumetric 
soft ware to measure the diameter and volume doubling 
time of a nodule between scans has been used success-
fully in screening trials to improve the sensitivity, 
specifi city, and negative predictive value of CT scans. 28 
Similarly, volumetric measurements added to tradi-
tional nodule malignancy prediction models have also 
been shown to improve the classifi cation of malignancy 
from 60% to 80%, with better performance than that 
of the traditional model. 29 Identifi cation of aberrations 
in airway epithelial cell gene expression, circulating 
tumor antibodies, plasma proteomics, exhaled breath 
analysis, and microRNA are all being studied actively 
for use in diagnosing lung cancer. 30-35 Th ese novel tests 
have the potential to further refi ne nodule management 
 Figure 3 – PET scan use grouped based on most invasive procedure. A, Surveillance. B, Biopsy. C, Surgery. 
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and alleviate the ambiguity of current management 
strategies. 
 Th is study has several limitations. First, the retrospective 
design precluded a complete understanding of the ratio-
nale for test ordering. However this design did allow 
for a defi nitive fi nal diagnosis to be established with 
biopsy, surgery, or 2 years of radiographic surveillance. 
Second, incomplete PET scan data coupled with diffi  -
culties in scan interpretation resulted in variations in 
the defi nition of a “positive” PET scan. To overcome 
this limitation, we developed a hierarchical algorithm 
for determining a defi nitive PET scan result. Finally, 
excluding patients who had had a CT scan  . 60 days 
prior to initial consultation may have selectively 
excluded some patients with low probability nodules. 
 Th is study also has several strengths. Th e fi ndings are 
generalizable because of the large sample size, geographic 
distribution, and multicenter design. Th e study also 
focuses on a size range of nodules (8-20 mm) that most 
oft en presents a diagnostic dilemma for physicians. 16 
Nodules smaller than 8 mm are followed with surveil-
lance because the pCA is low, PET scans do not reliably 
characterize small nodules, and biopsy of small nodules 
is diffi  cult; by contrast, nodules  . 20 mm are likely to 
undergo biopsy or surgery because the pCA is high. As 
opposed to other published series, this study allowed for 
all three management strategies to be studied in detail. 
 Conclusions 
 In conclusion, one in four patients referred with a nod-
ule to a community pulmonologist has cancer, making 
management decisions critical to patient outcomes. To 
spare patients unnecessary testing, use of a higher pCA 
to defi ne a nodule as low risk seems reasonable. Th ere 
is a wide variation in how nodules are managed and the 
choice of management may be infl uenced by a variety of 
factors in addition to pretest probability. Future research 
should focus on what infl uences decision-making in PN 
management so that interventions may be developed to 
promote proper guideline adherence and avoidance of 
unnecessary invasive procedures. 
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